DBV Technologies Presents Its Strategy at the Biotech Summit
DBV Technologies announces the participation of its CEO at a major conference organized by Guggenheim Securities. This presentation is part of the biopharmaceutical company's institutional communication with investors and industry stakeholders.
Daniel Tassé, CEO of DBV Technologies, will speak on Thursday, February 12, 2026, at 2:30 PM Eastern Time during the Guggenheim Securities Emerging Outlook: Biotech Summit, which will be held in New York on February 11 and 12, 2026. His appearance will take the form of an informal discussion ('fireside chat'), a classic format for engaging with investors at specialized conferences.
Live Webcast and Recording Details
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
A live webcast of the 'fireside chat' will be available on the company's website in the Investors / Events section. A recording will remain accessible for 90 days following the event. DBV Technologies continues to specialize in the development of treatments for food allergies and immunological conditions, focusing its efforts on the use of its proprietary technology, the VIASKIN® patch, with ongoing clinical studies particularly in young children allergic to peanuts.
Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
Financement pouvant atteindre 306,9 millions de dollars via PIPE
Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
